| 2.25 -0.01 (-0.44%) | 05-29 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.75 | 1-year : | 2.92 |
| Resists | First : | 2.35 | Second : | 2.5 |
| Pivot price | 2.27  |
|||
| Supports | First : | 2.11 | Second : | 1.76 |
| MAs | MA(5) : | 2.26  |
MA(20) : | 2.29 |
| MA(100) : | 6.17 |
MA(250) : | 4.42 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 37.7 |
D(3) : | 38.3 |
| RSI | RSI(14): 33.9 |
|||
| 52-week | High : | 12.36 | Low : | 1.8 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ LPCN ] has closed above bottom band by 37.5%. Bollinger Bands are 94.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 25 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.3 - 2.31 | 2.31 - 2.32 |
| Low: | 2.18 - 2.2 | 2.2 - 2.21 |
| Close: | 2.23 - 2.25 | 2.25 - 2.27 |
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis; LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the management of decompensated cirrhosis; LPCN 1154, an investigational new drug application to conduct a Phase 2 study in Postpartum depression; LPCN 2101 for women with epilepsy, which has completed pre-clinical study; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.
Tue, 26 May 2026
[8-K] Lipocine Inc. Reports Material Event - Stock Titan
Tue, 19 May 2026
Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting - PR Newswire
Tue, 19 May 2026
Oral postpartum depression trial to be showcased at 2026 ASCP meeting - Stock Titan
Mon, 18 May 2026
Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase - PR Newswire
Mon, 18 May 2026
Lipocine (NASDAQ: LPCN) plans fireside chat at A.G.P. Annual Healthcare Company Showcase - Stock Titan
Thu, 07 May 2026
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026 - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 8 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 4.6 (%) |
| Held by Institutions | 23 (%) |
| Shares Short | 154 (K) |
| Shares Short P.Month | 152 (K) |
| EPS | -1.97 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.34 |
| Profit Margin | 0 % |
| Operating Margin | -219.7 % |
| Return on Assets (ttm) | -32.9 % |
| Return on Equity (ttm) | -54.3 % |
| Qtrly Rev. Growth | -67.2 % |
| Gross Profit (p.s.) | 0.24 |
| Sales Per Share | 0.24 |
| EBITDA (p.s.) | -1.26 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -10 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -1.15 |
| PEG Ratio | 0 |
| Price to Book value | 0.95 |
| Price to Sales | 9.36 |
| Price to Cash Flow | -1.9 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|